Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 15/20 | 1.00 |
| ▸ | POLB | P06746 | 13/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 1.00 |
| ▸ | PKM | P14618 | 11/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 10/20 | 1.00 |
| ▸ | LMNA | P02545 | 10/20 | 1.00 |
| ▸ | TSHR | P16473 | 8/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | CREBBP | Q92793 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.82 |
| ▸ | NPSR1 | Q6W5P4 | 7/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.82 |
| ▸ | ESR1 | P03372 | 5/20 | 0.82 |
| ▸ | RECQL | P46063 | 4/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.82 |
| ▸ | HTT | P42858 | 4/20 | 0.82 |
| ▸ | MEN1 | O00255 | 3/20 | 0.82 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.82 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2014615 | 0.99 | SMN1; SMN2 (0.98) | SMN1; SMN2POLBALDH1A1PKML3MBTL1 | |
| SCHEMBL2016219 | 0.93 | SMN1; SMN2 (0.87) | SMN1; SMN2POLBALDH1A1PKML3MBTL1 | |
| SCHEMBL2014912 | 0.90 | POLB (1.00) | SMN1; SMN2POLBALDH1A1PKML3MBTL1 | |
| SCHEMBL2017060 | 0.90 | SMN1; SMN2 (0.81) | SMN1; SMN2POLBALDH1A1PKML3MBTL1 | |
| SCHEMBL2016888 | 0.89 | POLB (0.84) | SMN1; SMN2POLBALDH1A1PKML3MBTL1 | |
| SCHEMBL2017482 | 0.89 | POLB (0.85) | SMN1; SMN2POLBALDH1A1PKML3MBTL1 | |
| SCHEMBL2015501 | 0.89 | POLB (1.00) | SMN1; SMN2POLBALDH1A1PKML3MBTL1 | |
| SCHEMBL2021255 | 0.87 | POLB (0.83) | SMN1; SMN2POLBALDH1A1PKML3MBTL1 | |
| SCHEMBL2015999 | 0.87 | ALDH1A1 (0.79) | SMN1; SMN2POLBALDH1A1PKML3MBTL1 | |
| SCHEMBL2020989 | 0.87 | SMN1; SMN2 (1.00) | SMN1; SMN2POLBALDH1A1PKML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3087068-B1 | STK 405759 FOR THE TREATMENT OF MULTIPLE MYELOMA OR MYELOFIBROSIS | TEL HASHOMER MEDICAL RES INFRASTRUCTURE & SERVICES LTD (IL) | 2019-09-25 | — | — | EP | claimed |
| US-9782387-B2 | Compositions and methods for treating hematological malignancies | TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. (IL) | 2017-10-10 | — | — | US | claimed |
| WO-2011073929-A1 | 6-(2-FURYL)-3-METHYL-4-OXO-1,5,6,7-TETRAHYDROINDOLE-2-CARBOXYLATE DERIVATIVES AND USES THEREOF | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2011-06-23 | — | — | WO | claimed |
| WO-2024069634-A1 | MICROTUBULE TARGETING AGENTS | Ariel Scientific Innovations Ltd. (IL) | 2024-04-04 | — | — | WO | disclosed |
| EP-3087068-B1 | STK 405759 FOR THE TREATMENT OF MULTIPLE MYELOMA OR MYELOFIBROSIS | TEL HASHOMER MEDICAL RES INFRASTRUCTURE & SERVICES LTD (IL) | 2019-09-25 | — | — | EP | disclosed |
| EP-3087068-B1 | STK 405759 FOR THE TREATMENT OF MULTIPLE MYELOMA OR MYELOFIBROSIS | TEL HASHOMER MEDICAL RES INFRASTRUCTURE & SERVICES LTD (IL) | 2019-09-25 | — | — | EP | disclosed |
| US-9782387-B2 | Compositions and methods for treating hematological malignancies | TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. (IL) | 2017-10-10 | — | — | US | disclosed |
| US-9782387-B2 | Compositions and methods for treating hematological malignancies | TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. (IL) | 2017-10-10 | — | — | US | disclosed |
| US-20160303080-A1 | COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES | TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. (IL) | 2016-10-20 | — | — | US | disclosed |
| US-20160303080-A1 | COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES | TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. (IL) | 2016-10-20 | — | — | US | disclosed |
| WO-2015097691-A1 | COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES | TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. (IL) | 2015-07-02 | — | — | WO | disclosed |
| WO-2011073929-A1 | 6-(2-FURYL)-3-METHYL-4-OXO-1,5,6,7-TETRAHYDROINDOLE-2-CARBOXYLATE DERIVATIVES AND USES THEREOF | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303080-A1 | COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES | MCL1, BCL9, THPO | SMN1; SMN2 1424/4885POLB 1071/4885ALDH1A1 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.